Despite impressive data supporting HMA/Venetoclax, its application in younger, fit patients must be cautious. The pivotal VIALE-A trial excluded key subgroups like FLT3, core binding factor, and certain NPM1 patients, for whom intensive chemotherapy remains the standard.

The PARADIGM trial, showing Aza/Venetoclax is superior to intensive chemo for younger, fit patients, is not a universal finding. It explicitly excluded patients with favorable-risk cytogenetics and FLT3 mutations, meaning it applies mainly to a higher-risk subset.

The FLAG-IDA plus venetoclax regimen achieves very high MRD-negative remission rates. However, its similar efficacy in both frontline and first salvage settings suggests it might be more strategically deployed as a salvage therapy, avoiding its high toxicity in all patients upfront.

For IDH1-mutated AML patients who have failed venetoclax—a notoriously difficult-to-treat population with a 3-4 month median survival—Eludacidinib has demonstrated some of the best-reported outcomes. This carves out a clear clinical niche for the drug in this specific salvage setting.

The IDH1 inhibitor olutasidenib demonstrates a much longer duration of response than ivosidenib. One hypothesis is that olutasidenib's weaker affinity for wild-type IDH1 makes it a more selective inhibitor of the mutant protein, leading to more durable disease control.

To combat the significant myelosuppression from the standard 28-day venetoclax cycle in AML, many clinicians are adopting a strategy of performing a bone marrow biopsy around day 21 and pausing the drug if blast clearance is achieved to allow for hematologic recovery.

When an AML patient presents with multiple targetable mutations (FLT3, NPM1, IDH), clinicians follow a treatment hierarchy. FLT3-targeted therapy is typically the first choice due to its aggressive phenotype. Menin inhibitors for NPM1 are next, followed by IDH inhibitors, guiding treatment decisions in complex cases.

Mesutoclax's key advantages over the established BCL-2 inhibitor venetoclax are practical. It is designed to minimize prolonged myelosuppression and, critically, avoids significant drug-drug interactions with common antifungals. This simplifies real-world management for elderly patients on multiple medications, addressing a major logistical headache for clinicians.

While adding a menin inhibitor to the azacitidine/venetoclax doublet for older/unfit AML patients increases response rates, it leaves little reserve for marrow function. This can lead to increased risk of early, fatal complications like infection or bleeding, requiring careful dose management.